fda bpc-157 not approved safety warning Next week, July 23-24, the FDA's Pharmacy Compounding Advisory Committee will review seven peptides being considered for inclusion on the 503A Bulks List. Why does this matter? If these peptides are ultimately What's behind the push to
Description
Not because of safety concerns per se, but because it becomes impossible to know whats actually working
Recent studies have demonstrated the feasibility of producing mRNA-encoded antibodies against viral targets such as SARS-CoV-2 and Ebola virus
The agency would have to solicit public comment and an advisory committee of health and pharmacy experts would have to review the FDAs research
Methods: RECOVER-S is a multi-center, stroke rehabilitation cohort investigating clinical trajectories and rehabilitation pathways of patients in Berlin, Germany (trial identifier: DRKS00030023)
